{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1021.11",
  "meta" : {
    "versionId" : "13",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "TJC EH Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-keyWord",
      "valueString" : "Not_In_Use"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-04-02"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2016-03-31"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.11",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1021.11"
    }
  ],
  "version" : "20160331",
  "name" : "InjectableFactorXaInhibitorForVTEProphylaxisIngredientSpecific",
  "title" : "Injectable factor Xa inhibitor for VTE prophylaxis ingredient specific",
  "status" : "retired",
  "experimental" : false,
  "date" : "2016-03-31T01:00:12-04:00",
  "publisher" : "TJC EH Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: Injectable factor Xa inhibitors for VTE prophylaxis as independent ingredients for use in noting the most general idea of this type of therapy. Initial use is for representation of a medication \"not done\". The desire is to have a single choice.),(Data Element Scope: Medication order or discharge NOT DONE),(Inclusion Criteria: Only single ingredient, ingredient-level representation of Injectable factor Xa inhibitors for VTE prophylaxis.),(Exclusion Criteria: None.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept" : [
          {
            "code" : "321208",
            "display" : "fondaparinux"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:2fb23b05-aa4d-41ec-8046-2bf830e1e4c2",
    "timestamp" : "2024-06-14T09:15:29-04:00",
    "total" : 1,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "321208",
        "display" : "fondaparinux"
      }
    ]
  }
}
